Present findings show that RAS mutations were enriched in MCRC patients, compared to early CRC where KRAS2–4 37.8%, and NRAS2–4 4.6% mut were reported by the same NGS platform [13, 14]. This evidence concerns the gene KRAS and colorectal carcinoma.